Cellectis is undergoing a significant business transformation, leading to potential job cuts. The company is shifting its focus from CAR T cell therapies to in vivo gene editing treatments. This strategic pivot could result in up to 70% of its global workforce being laid off. Enrollment has ceased for its CAR T programs as the company prioritizes its in vivo candidates. These changes are expected to impact employees through 2027.
https://www.biospace.com/job-trends/cellectis-could-cut-70-of-workforce-in-shift-to-in-vivo-therapies